$AZN

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.

Chinese biotech Jacobio Pharmaceuticals expects profitability in 2026 via $100M AstraZeneca deal for KRAS inhibitor and growing Glecirasib sales.

DelveInsight's 2026 report reveals robust clinical pipeline for pseudomonal infections, with major pharma including AstraZeneca advancing promising therapies addressing antibiotic-resistant pathogens.

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.

International stocks trade at cheaper valuations than U.S. peers, with $SCHF offering low-cost exposure. Outperformance continued into 2026 despite currency risks.

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

CDT Equity acquires 20% stake in Sarborg AI for $115M while advancing AstraZeneca-licensed pharmaceuticals and exploring capital markets options.

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.

Acute ischemic stroke market poised for significant growth through 2036, driven by novel therapies including recently approved tenecteplase and promising pipeline candidates addressing 1.8 million annual cases.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

FDA approves first all-oral combination therapy for untreated chronic lymphocytic leukemia. The fixed-duration treatment showed 35% reduced progression risk versus chemotherapy.

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.